生命科学资讯

Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy

Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial

J&J joins 'menin party' at ASH; GSK to work with Oxford BioTherapeutics

Stifel reiterates Buy rating on Illumina stock, cites multiple growth levers - Investing.com UK

Adaptations of the axon initial segment in fast-spiking interneurons of the human neocortex support low action potential thresholds

New recombinant strain of mpox virus identified in the UK

Solving the AAV Titer Challenge: A New Approach to Gene Therapy Workflows

#SABCS25: Roche’s breast cancer pill cuts post-surgery disease recurrence risk by 30%

Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial - Fierce Biotech

Will 2026 be pharma’s M&A breakout year?

Another genetic testing company? Why a different approach could boost drug predictions and R&D.

Prelude Therapeutics divulges new JAK2 inhibitors

Amgen describes new GTPase KRAS mutant inhibitors

New CDK2 and CDK4 degradation inducers disclosed in Nikang Therapeutics patent

Immuse Therapeutics discovers new LRRK2 inhibitors

PsiThera gets $47.5M for oral I&I drugs after spinning out from Roivant

Formation Bio signs deal for TYK2 drug from China's Lynk

A former Roivant spinout bets on AI-designed drugs for immune conditions

UK lowers new medicine rebate scheme to 14.5% for 2026